Vidya Puthenpura, Kinjal Desai, Andrew Bauer, Ian Marshall
{"title":"Delayed methimazole-induced agranulocytosis in a 6-year old patient with Graves' disease.","authors":"Vidya Puthenpura, Kinjal Desai, Andrew Bauer, Ian Marshall","doi":"10.1186/s13633-016-0034-6","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Agranulocytosis is regarded as a rare side effect of methimazole (MMI) therapy that occurs in a dose dependent manner and that usually develops within the first 3-6 months of treatment. Although delayed development beyond this timeline has been documented in adults, very few children have been reported with this presentation.</p><p><strong>Case presentation: </strong>We present a 6-year old patient who developed agranulocytosis 18 months after the start of MMI therapy.</p><p><strong>Conclusions: </strong>This is an unusual case of a 6-year old patient who developed this serious side effect on stable MMI therapy well beyond the typical timeline. Our review of the literature revealed that there really is inconclusive data on the incidence, time, and dose-dependency of MMI-induced agranulocytosis in the pediatric Graves' disease population.</p>","PeriodicalId":14271,"journal":{"name":"International Journal of Pediatric Endocrinology","volume":"2016 1","pages":"16"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s13633-016-0034-6","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pediatric Endocrinology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s13633-016-0034-6","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/9/6 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
Background: Agranulocytosis is regarded as a rare side effect of methimazole (MMI) therapy that occurs in a dose dependent manner and that usually develops within the first 3-6 months of treatment. Although delayed development beyond this timeline has been documented in adults, very few children have been reported with this presentation.
Case presentation: We present a 6-year old patient who developed agranulocytosis 18 months after the start of MMI therapy.
Conclusions: This is an unusual case of a 6-year old patient who developed this serious side effect on stable MMI therapy well beyond the typical timeline. Our review of the literature revealed that there really is inconclusive data on the incidence, time, and dose-dependency of MMI-induced agranulocytosis in the pediatric Graves' disease population.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
